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OBJECTIVE: There is controversy about the clinical consequences of intermediate
alleles (IAs) in Huntington disease (HD). The main objective of this study was to
establish the clinical manifestations of IA carriers for a prospective, international,
European HD registry.
METHODS: We assessed a cohort of participants at risk with <36 CAG repeats of
the huntingtin (HTT) gene. Outcome measures were the Unified Huntington's
Disease Rating Scale (UHDRS) motor, cognitive, and behavior domains, Total
Functional Capacity (TFC), and quality of life (Short Form-36 [SF-36]). This cohort
was subdivided into IA carriers (27-35 CAG) and controls (<27 CAG) and younger
vs older participants. IA carriers and controls were compared for
sociodemographic, environmental, and outcome measures. We used regression
analysis to estimate the association of age and CAG repeats on the UHDRS scores.
RESULTS: Of 12,190 participants, 657 (5.38%) with <36 CAG repeats were
identified: 76 IA carriers (11.56%) and 581 controls (88.44%). After correcting for
multiple comparisons, at baseline, we found no significant differences between IA
carriers and controls for total UHDRS motor, SF-36, behavioral, cognitive, or TFC
scores. However, older participants with IAs had higher chorea scores compared
to controls (p = 0.001). Linear regression analysis showed that aging was the most
contributing factor to increased UHDRS motor scores (p = 0.002). On the other
hand, 1-year follow-up data analysis showed IA carriers had greater cognitive
decline compared to controls (p = 0.002).
CONCLUSIONS: Although aging worsened the UHDRS scores independently of
the genetic status, IAs might confer a late-onset abnormal motor and cognitive
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